Immuno-OncologyVeröffentlicht am: 17. Okt. 2017
PACIFIC: Quality of Life is maintained in NSCLC patients treated with durvalumab
In the randomised, double-blind phase III trial PACIFIC, durvalumab has shown to improve PFS while upholding quality of life measures in locally advanced, unresectable NSCLC patients after concurrent chemoradiation.